Loading...
Thumbnail Image
Publication

Opioid medication use and blood DNA methylation: epigenome-wide association meta-analysis

Lee, Mikyeong
Joehanes, Roby
McCartney, Daniel L
Kho, Minjung
Hüls, Anke
Wyss, Annah B
Liu, Chunyu
Walker, Rosie M
R Kardia, Sharon L
Wingo, Thomas S
... show 10 more
Embargo Expiration Date
Abstract

Aim: To identify differential methylation related to prescribed opioid use. Methods: This study examined whether blood DNA methylation, measured using Illumina arrays, differs by recent opioid medication use in four population-based cohorts. We meta-analyzed results (282 users; 10,560 nonusers) using inverse-variance weighting. Results: Differential methylation (false discovery rate <0.05) was observed at six CpGs annotated to the following genes: KIAA0226, CPLX2, TDRP, RNF38, TTC23 and GPR179. Integrative epigenomic analyses linked implicated loci to regulatory elements in blood and/or brain. Additionally, 74 CpGs were differentially methylated in males or females. Methylation at significant CpGs correlated with gene expression in blood and/or brain. Conclusion: This study identified DNA methylation related to opioid medication use in general populations. The results could inform the development of blood methylation biomarkers of opioid use.

Source

Lee M, Joehanes R, McCartney DL, Kho M, Hüls A, Wyss AB, Liu C, Walker RM, R Kardia SL, Wingo TS, Burkholder A, Ma J, Campbell A, Wingo AP, Huan T, Sikdar S, Keshawarz A, Bennett DA, Smith JA, Evans KL, Levy D, London SJ. Opioid medication use and blood DNA methylation: epigenome-wide association meta-analysis. Epigenomics. 2022 Dec;14(23):1479-1492. doi: 10.2217/epi-2022-0353. Epub 2023 Jan 26. PMID: 36700736; PMCID: PMC9979153.

Year of Medical School at Time of Visit
Sponsors
Dates of Travel
DOI
10.2217/epi-2022-0353
PubMed ID
36700736
Other Identifiers
Notes
Funding and Acknowledgements
Corresponding Author
Related Resources
Related Resources
Repository Citation
Rights
Open access This work is licensed under the Creative Commons Attribution 4.0 License. To view a copy of this license, visit http://creativecomm ons.org/licenses/by/4.0/Attribution 4.0 International